Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Omacetaxine mepesuccinate
Drug ID BADD_D01609
Description Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the plant, Cephalotaxus species. In October 2005, omacetaxine mepesuccinate received Orphan Drug designation from the EMEA for the treatment of chronic myeloid leukemia (CML). Then in March 2006, it received Orphan Drug status from the FDA for the treatment of CML. In November 2006, omacetaxine mepesuccinate, for the treatment of CML, was granted Fast Track designation by the FDA. Most recently, in October 2012, omacetaxine mepesuccinate was marketed under the brand name Synribo and FDA approved for patients who are intolerant and/or resistant to two or more tyrosine kinase inhibitors used to treat accelerated or chronic phase CML.
Indications and Usage Not Available
Marketing Status Prescription
ATC Code L01XX40
DrugBank ID DB04865
KEGG ID D08956
MeSH ID D000077863
PubChem ID 285033
TTD Drug ID D0M4XY
NDC Product Code 63459-177; 69605-732; 62422-0003
Synonyms Homoharringtonine | Omacetaxine Mepesuccinate | Cephalotaxine | Omacetaxine | Homoharringtonine (3(R))-isomer | Ceflatonin | Synribo
Chemical Information
Molecular Formula C29H39NO9
CAS Registry Number 26833-87-4
SMILES CC(C)(CCCC(CC(=O)OC)(C(=O)OC1C2C3=CC4=C(C=C3CCN5C2(CCC5)C=C1OC)OCO4)O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Febrile neutropenia08.05.02.004; 01.02.03.0020.001066%
Gait disturbance17.02.05.016; 08.01.02.0020.000533%
Gastritis07.08.02.001--
Gastrooesophageal reflux disease07.02.02.003--
Gastrointestinal disorder07.11.01.0010.000533%Not Available
Gastrointestinal haemorrhage24.07.02.009; 07.12.02.001--Not Available
Generalised oedema14.05.06.007; 08.01.07.004--
Gingival bleeding24.07.02.010; 07.09.07.001--Not Available
Gingival pain07.09.04.001--
Gingivitis07.09.03.003; 11.01.04.013--
Gout15.01.06.001; 14.09.01.0010.000533%Not Available
Granulocytopenia01.02.03.0030.000533%Not Available
Haematoma24.07.01.001--
Haemoglobin decreased13.01.05.0030.001865%Not Available
Haemoptysis24.07.01.006; 22.02.03.004; 02.01.02.006--Not Available
Haemorrhoids24.10.02.002; 07.15.03.001--
Headache17.14.01.0010.001865%
Hyperglycaemia14.06.02.002; 05.06.02.002--
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hypersensitivity10.01.03.0030.000533%
Hypertension24.08.02.001--
Hyperthermia12.05.01.002; 08.05.01.001--Not Available
Hypoaesthesia17.02.06.023--Not Available
Hypotension24.06.03.002--
Infection11.01.08.0020.000139%Not Available
Influenza like illness08.01.03.0100.000533%
Injection site reaction12.07.03.015; 08.02.03.014--
Insomnia19.02.01.002; 17.15.03.002--
Lacrimation increased06.08.02.004--
Laryngeal pain22.02.05.036--
The 3th Page    First    Pre   3 4 5 6    Next   Last    Total 6 Pages